WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST Without groundbreaking science, it’s certain the biopharma industry wouldn’t be a trillion-dollar enterprise. In the second entry of its four-part series, Fierce Pharma looks at this year's most influential scientists and their impacts on the field. Meanwhile, Fierce Biotech looks at the executives tasked with putting those findings into practice—and the most well-compensated among them. Last year saw tectonic shifts in pay among R&D leaders, with reductions for some and boosts for others, bringing some newcomers to the top 10. Those special reports plus our top stories of the week follow below. | |
|
Featured Story | By Eric Sagonowsky,Kevin Dunleavy,Max Bayer,Andrea Park,Gabrielle Masson Without science, biopharma wouldn't exist. Without new, groundbreaking science, it might exist, but it wouldn't be very exciting—and it certainly wouldn't be a trillion-dollar enterprise. That's why our look at this year's most influential people had to turn to scientists next. read more |
| |
|---|
|
|  | Webinar: Workplaces Have Changed. How Are You Managing Yours? Wednesday, June 1 | 11am ET / 8am PT Optimizing your diverse spaces, while giving employees an exceptional experience, is more important than ever. Learn how the Connected Workplace for Life Sciences can help you support the full lifecycle of your buildings, spaces, and every asset within them all on one platform. Register now. |
Top Stories Of The Week By Max Bayer The top 10 list of the highest-paid biopharma R&D execs looks a little bit different in 2021 than the year before after a number of pendulum swings in pay. And the new top 2 earners have since left their top research posts for CEO roles elsewhere. read more By Eric Sagonowsky Only a month after mRNA giant Moderna unveiled a CFO switch, its new finance chief is out the door because his former employer disclosed an internal accounting probe. As a result, Moderna is bringing back its former finance chief David Meline to run its books. read more By Gabrielle Masson After two recent layoff rounds, BridgeBio Pharma is looking to out-license six of its candidates to save capital. The biotech has been hit by the burden of the bear market after disclosing disappointing phase 3 results last year. read more By Kevin Dunleavy A police report of the domestic abuse arrest of Seagen CEO Clay Siegall, Ph.D., describes a drunken night involving him, his wife and another couple and includes sexual escapades and alleged violence that led Siegall to be taken to jail. read more By Max Bayer After selling its potential blockbuster migraine program to Pfizer, Biohaven is hoping to strike gold twice. Its immediate future rests with two looming phase 3 readouts, the first of which is due in a few weeks. read more By Angus Liu Declining sales of its lead cancer drug, a need to raise additional capital and a 30% stock price plunge depict the nightmare Clovis Oncology is living through right now. But that’s not all. read more By Max Bayer Regulators gave VistaGen the green light to continue developing its nasal spray to treat social anxiety without an additional trial to measure its abuse risks. VistaGen is expecting data from its first phase 3 trial in the coming weeks. read more By Zoey Becker Emergent BioSolutions' COVID-19 vaccine manufacturing woes were well documented in 2021, but a new congressional probe found that the company's problems went much further than realized. read more By Max Bayer A global team of scientists may have inadvertently discovered a potential treatment for one of the root causes of dementia. The researchers say when under stress, the endoplasmic reticulum actually reversed the build-up of protein "aggregates" caused by misfolding, a mechanism that can result in neurodegenerative diseases. read more By Ben Adams Bristol Myers Squibb launched two education campaigns for the condition its new heart drug Camzyos treats, with Utah Jazz player Jared Butler headlining. The aim? Increase diagnosis of obstructive hypertrophic cardiomyopathy, a disease that until now has had no specific treatments. read more By Conor Hale The FDA said the Lumipulse test developed by Fujirebio Diagnostics could allow some patients to skip PET brain scans for finding amyloid plaques. read more By Teresa Carey This week on "The Top Line," we talk about why Big Pharma is resisting the temptation to go on a biotech M&A spree. We also discuss the 10 biggest earners among R&D chiefs and the drastic changes from last year's list, plus the week's biggest headlines. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. | 
